Publikationer och vetenskapliga presentationer

Publikationer

Järås et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL1 receptor accessory protein.

www.pnas.org/content/early/2010/08/24/1004408107


Askmyr et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP

www.bloodjournal.org/content/121/18/3709


Ågerstam et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

Proc Natl Acad Sci USA. PNAS 2015 Aug 112 (34) 10786-10791


Ågerstam et al. IL1RAP antibodies block IL1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Blood 2016 DOI 10.1182/blood-2015-11-679985


Posters

Blocking IL1, IL33 and IL36 signalling by an anti IL1RAP antibody is an efficient anti-inflammatory treatment that improves heart function in a model of autoimmune myocarditis – IMMUNOLOGY 2021 AAI annual meeting

Can10 Poster Presentation American Association Of Immunologists Aai Virtual Immunology 2021


Glycoengineered murine antibodies as surrogates to the humanized and ADCC-enhanced anti-IL1RAP antibody CAN04 – Protein & Antibody Engineering Europe 2019

Poster Pegs Europe 2019 Final


The CAN04 Antibody Targets IL1RAP and Mediates Tumor Growth Inhibition and Increased Cisplatin Sensitivity in a Patient-Derived Xenograft Model for Non-Small Cell Lung Cancer - Antibody Engineering and Therapeutics 2018

https://cantargia.com/assets/uploads/Poster-San-Diego.pdf


A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors - ESMO Annual Meeting 2018

https://cantargia.com/assets/uploads/Poster-CANFOUR-ESMO-2018-version-FINAL.pdf


Antibody blockade of IL1RAP signaling reduces metastasis in a breast cancer model - AACR Annual Meeting 2018

https://cantargia.com/assets/uploads/Poster-AACR-2018-final.pdf


The CAN04 Antibody Targets IL1RAP and Inhibits Tumor Growth in a PDX Model for NSCLC - Protein & Antibody Engineering 2016

https://cantargia.com/assets/uploads/Poster-PEGS-Europe-final.pdf


Muntliga presentationer

Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumors - ASCO Annual Meeting 2019

https://cantargia.com/assets/uploads/ASCO2019_CANFOUR-Phase-I_FINAL-01June_2019.pdf


The CAN04 antibody targets IL1RAP and mediates tumor growth inhibition and increased cisplatin sensitivity in a patient-derived xenograft model for non-small cell lung cancer - Protein & Antibody Engineering 2018

https://cantargia.com/assets/uploads/Cantargia_San-Diego-CAN04-and-chemotherapy.pdf


IL1RAP as a therapeutic target - Protein & Antibody Engineering 2018

https://cantargia.com/assets/uploads/Cantargia_San-Diego-IL1RAP-as-therapeutic-target.pdf